Monday, April 30, 2018

Why Panic Can Accelerate the Therapies Discovery

Why Panic Can Accelerate the Therapies Discovery


Jesica Levingston Mac leod, PhD



In March, the Center of Disease Control (CDC) reported an outbreak of a “more virulent” Ebola virus infection in Guinea and Sierra Leone .Now, the disease has been spread to Liberia and Nigeria, among other West Africa countries. The final count is more than 1600 confirmed cases of Ebola hemorrhagic fever, with almost 900 deaths caused for this syndrome. Some of these cases included health-care workers. Indeed, two medical doctors were taken back to US to be treated with a new cocktail in the Emory University Hospital facilities in Atlanta, GA. Some Americans began to panic, for example Jon Stewart said in his show that “They are importing Ebola”.

Last week, two patients with Ebola like symptoms were all over the news. One of these cases happened in the New York City Mount Sinai Hospital, and the patient was isolated and tested right away. The hospital sent an email to all the employees updating them about the situation, and the press took over it. The bright side of the situation, in addition to the negative test result for Ebola virus, was the fast reply. The dark side was the paranoia and the lack of information and knowledge about this virus from the Manhattan community. It was alarming to read that some neighbors did not want to go to the emergency room in the hospital for fear to get infected. Well, you can’t get infected just for seating next to a sick person, or talk, or shake your hands: it is not an airborne transmitted virus.

The other problem is that the symptoms are pretty similar to other more “common” diseases: Fever, rash, severe abdominal pain, vomiting, and bleeding, both internally and externally. The difference is that the fatality rate is more than 60%. The transmission of the virus mostly occurs by contact with infected blood, secretions or organs of either bats, nonhuman primates or humans. This is why you should not eat bats or monkeys if you visit any of the affected areas, or hang around any cemeteries. Not surprisingly, Ebola was named as the most frightening disease in the world. It was documented for the first time in 1976 in the Republic of Congo; one of the sources came from the Ebola River.



In 2012 an outbreak in Uganda found us in a similar medical emptiness: the research of two of the vaccines that were “apparently” going great had been canceled by the department of defense, due to funding constraints. Therefore, so far we do not have any vaccine or effective treatment available.

In 2009, Dr. Feldmann, by then working in Canada (now in Montana, US), developed a vaccine that was used years after in Germany when a researcher accidentally pricked her finger with a syringe containing Ebola The Feldmann’s vaccine consists in a recombinant vesicular stomatitis virus expressing the Ebola glycoprotein which protects macaques from Ebola virus infections; although this method is not licensed for human use and the government founding has been random. A similar vaccine has been produce by Profectus BioSciences in Tarrytown, New York, but they are also short in the monetary founding that will push the research to the human trials.

The famous ZMapp serum, the treatment that the 2 Americans are receiving, is a cocktail of humanized, three-monoclonal- antibodies. This “cure” was the result of the collaboration of 25 laboratories among seven countries. The project, funded by the National Institute of Allergy and Infectious Diseases (NIAID), has a total budget of $28 millions. The scientific leader is the Dr. Erica Ollmann-Shapire, whom claimed that she would take the cocktail without doubts if she would be infected. Also the company Mapp Biopharmaceutical, based in California, is the principal producer of these antibodies. The initial trials in macaques were very successful, but the approval for the use in human trial is pending until 2015.

A lot of laboratories along the world are working towards the better understanding of the Ebola virus and the possible vaccines and cures. Most of these researches are founded by the US Department of Defense. But, why does the US Department of Defense care about an African virus? The answer is pretty obvious: it can be used as a bio hazard weapon. On the other hand, no leading pharmaceutical is going to invest in a “very expensive and time consuming” vaccine development to be used in countries that can’t afford even a basic level of health care. Some compounds are showing a promising antiviral effect in vitro and/or an inhibition of a variety of viral proteins activities. Sadly, all of them are in an early stage of drug development. On the other hand,the actual need for a therapy and a vaccine to stop this outbreak is speeding the drug development process.



Before freaking out, the best prevention method against this scaring virus is knowledge, so check out the updates in the CDC website.

Squeezed Science – Should We Switch to a Business Mindset?

Squeezed Science – Should We Switch to a Business Mindset?


By Jesica Levingston Mac leod, PhD

It is a common conversation topic among researchers, but it was not until the NPR article saw the light, and the dark side, that the public realized the problems that young scientists are facing when pursuing a successful career in Academia. As we raise awareness about these tribulations, my colleagues mentioned how a “postdoc”’s quality life depends on the quality of the lab, the institution, the project, the relationships with colleagues and the Principal investigator or PI (the boss), not forgetting that this is a very self driven career. So, if your hypothesis is very difficult to prove, or you have been hitting your head against the wall with all the negative results that took you years to get, you may eventually come to hating this path and leaving Academia. The same if you have been working in a non “hot field” where the funding sources do not consider interesting enough to support or your PI is not supportive, or you have a very wicked competence inside or outside the lab. All these negative situations can aggravate the perspective of the very little options one may have by pursuing a career in Academia. On the other hand, if you are obtaining excellent results, publishing in top tier journals, made hundreds of good connections and collaborators, have a “great boss” and literally love you job… well, probably you are also doomed…

One solution could be implementing the business approach to the scientific mindset: Why only having one PI per lab? At the end, two minds think more than 1. Perhaps collaborative research centers have a solution were 2 or more PIs can have access to more equipment, grants and professionals, and therefore use the best skills needed for the job, like a company where you have an executive committee and you distribute the stock between the employees, in order to make them be part of the enterprise.

Having a business mindset would mean to have a planed strategy about your career development. Having a backup career plan is one example of this: starting to apply for jobs before needed, or before it is too late. Begin with your preparation to be a leader, and make your PI know, and discuss a good starting point. Look for leadership opportunities in any situations, such as coordinating workshops or conferences.

Sign up to run workshops and career developing series!. Many postdocs can discover a great professional gain if these opportunities would be offer to them. Get training in other expertise to be competitive in, for example, the investing or consulting field. Taking classes about how to give a class is a great example of a course that could be offered to postdocs and graduate students, in order to train them to explain and transfer their empirical knowledge to the next generation.

A month ago, at the Mount Sinai Postdoc symposium, Dr. Bruce Alberts (yes, THE Alberts, from “The Molecular Biology of the Cell” book) who spoke about “The Future of Biology: Keeping Science Healthy” and illustrated the dramatic changes in the age of the scientist successfully obtaining project grants from NIH. In contrast to 30 years ago, the average age of new investigators with PhD at initial RO1 was 36.8 year old, a large number of grants were awarded to scientist in their early 30s, but this tendency has been decreasing drastically, to the point where now, the mean age for receiving these prestigious grants is 42 years of age. Dr. Alberts, himself, made fun on the fact that he obtained his postdoc position, before been awarded with his PhD. (which actually his thesis was rejected the first time, delaying the whole process) and learned from his failures. He also pointed out that he got his professor position at a very young age, something that is almost impossible nowadays. He advocated for a change in this unfair situation, which cripples the young innovators from getting a start. Also, he encouraged researchers to get out of the lab and talk to the public about science and its importance. First, to attract/engage curious minds to the scientific field, and second to communicate “in simple language” what we do for 9 hours plus per day in the lab.

We must offer to all this new scientific minds the reality about the current situation of science, but we also need to fix it, so it is not going to turn into a snow ball and make disappear all the interest in pursuing a scientific career for the new generations. In a business mind-set we must recognize that the money is not only in the governmental funding, but also in private foundations and other organizations like angels or venture capitals. So go out there and try to pitch your science to investors.

If Only Santa Would be Real…When Are We Going to Have a Universal Flu Vaccine?

If Only Santa Would be Real…When Are We Going to Have a Universal Flu Vaccine?


By Jesica Levingston Mac leod, PhD

Wouldn’t it be great if the answer to that question was “next year” (yep, only a 1 month wait). Sadly, besides all the astonishing efforts of various researchers groups we are just entering the clinical studies that might lead towards a safe and effective vaccine.

Probably you already heard about the antigenic mismatch with the current vaccine (for the strain H3N2): this means that the strains used in the vaccine could potentially not completely cover one or more of the seasonal influenza virus varieties. Therefore, if you got the flu shot, you might get sick anyways.

The concept behind the universal vaccine is to bypass the antigenic mismatch problem and other issues related with the way in which the vaccines are formulated nowadays. As Drs. Natali Pica and Peter Palese explained last year (Pica et al. 2013), the vaccines are prepared year by year with the aim to protect against the virus strains that are predicted to circulate in the next period. But, and there is always a “but” in predictions, an unexpected mutation in the virus not contemplated in the vaccine production, could conclude in a pandemic.

The clue came from thinking outside of the box, and breaking with the traditional dogmas in flu vaccine production. When you get infected with the influenza virus, your immune system targets the head domain of the HA (Hemagglutinin) protein, so the current vaccine production approach was to aim for this antigen. The bad news is that this domain changes every year. The flu vaccines are based on inactivated viruses , when you receive this vaccine, you will generate antibodies to fight these specific HA proteins. In Dr. Palese’s lab they are focus on regions of influenza HA protein that are highly conserved across virus subtypes, like the stalk domain of the HA protein. Also, he is engineering different HA chimeras. This strategy has been really successful, showing protection in animal models (mice and ferrets), and the vaccines were approved to go to clinical trial next year. This universal vaccine offered good protection for pandemics H5N1 and H7N9 influenza viruses.

Another strategy, published in Nature Medicine (Sridhar et al.) reports that targeting conserved core proteins using virus-specific CD8+ T cells (lymphocytes or white blood cells with a vital role in the immune system) could provide a draft for a universal influenza vaccine. But… even the scientists implicated in the research were not very positive about how long is going to take to translate this technique to the “outside the lab” world.

The third strategy is coming from an Italian group (Vitelli et al. 2013), and this potential universal influenza vaccine is been tested in animal models by the FDA. This vaccine uses as a vector the virus PanAd3 (it was isolated from a great ape), which carries 2 genes that express proteins conserved among a variety of influenza viruses. The 2 viral proteins, the matrix protein (M1) and the nucleoprotein (NP), could be expressed for the human cells infected with the recombinant PanAd3 virus and immunize the patient against different influenza viruses.

Other entrepreneurial ideas are blooming around the world in order to solver the “influenza virus infection” problem. The influenza virus kills around 500,000 people annually worldwide (WHO), and affects very negatively the life of other hundreds of thousands. In fact, I do not know anybody who did not got the flu at least ones, I encourage to try to find somebody who was never sick with flu symptoms. This points out how universal this problem is and therefore it should get an universal solution soon.

You Can Help Cure Ebola!

You Can Help Cure Ebola!


By Jesica Levingston Mac leod, PhD

Since the start of the outbreak last March, Ebola virus has already taken more than 8.000 lives and infected more than 21.200 people, according to the Center for Disease Control (CDC). The panic raised from this situation rushed the testing of therapies to stop the outbreak and the research on the Ebola virus has seen a rebirth. Some research groups that have been working in this field for a long time can now openly ask for help. One of these groups is the one lead by Dr. Erica Ollman Shaphire at The Scripps Research Institute, California. In 2013 they published in Cell an analysis of the different conformations of Ebola VP40 (Viral Protein 40) aka the shape-shifting “transformer” protein. They reported 3 different conformations of this protein, and how this variety allows it to achieve multiple functions in the viral replication circle. This Ebola virus protein along with the glycoprotein would be used as target for anti viral research. In order to find new anti-virals, their approach is an in-silico scrutiny of thousands of compounds, using viral protein crystal structures in the in silico docking to find leads that may be tested in the lab as inhibitors. IBM is already helping them in this project, generating the World Community Grid to find drugs through the Outsmart Ebola Together project. Here is where you can start helping, as this project involves a huge amount of data and computing time, they need volunteers that can donate their devices spare computing time (android, computer, kindle fire, etc) to generate a faster virtual supercomputer than can accelerate the discover of new potential drugs. This approach has been shown to be successful for other diseases like HIV and malaria, so you are welcome to join the fight against Ebola virus: https://secure.worldcommunitygrid.org/research/oet1/overview.do.

If you do not have any of these devices (I hope you are enjoying the public library free computers), you can still help Dr. Shapire quest to discover new therapies against Ebola. Her group is now “working to support the salary of a computer scientist to help process the data we are generating with the world community grid” as she describes it. To help identify the most promising drug leads for further testing you can donate money on: www.crowdrise.com/cureebola.

Other groups that were mostly working on other viruses, like Flu, also joined the race to discover efficient therapies. For example, last month, the Emerging Microbes and Infections journal of the Nature Publishing Group published the identification of 53 drugs that are potential inhibitors of the Ebola virus. One of the authors of this paper is Dr. Carles Martínez-Romero, from Dr. Adolfo García-Sastre’s lab in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. In the study, Dr. Martínez-Romero and collaborators described how they narrowed the search from 2.816 FDA approved compounds to 53 potential antiviral drugs. This high-throughput screening was possible thanks to the use of the Ebola viral-like particle (VLP) entry assay. This allows studying Ebola viral entry without using the ”real”, full replicative virus. These 53 compounds blocked the entry of Ebola VLPs into the cell. Understanding how these market-ready compounds can inhibit Ebola entry and its infectious cycle will pave the way for a new generation of treatments against Ebola virus-associated disease.

Dr. Martínez-Romero had an early interest in science; “Since I was a child, I showed great interest in biological sciences and a great desire to question and discover. This led me to pursue my studies in Biotechnology in order to become a successful researcher.”Viruses are very interesting to me because, although they are not strictly living organisms, they are as old as life itself. Even though they are the origin of many illnesses in mammals and other organisms alike, we are tightly interconnected with viruses and they will continue shaping our evolution throughout the years to come.

I also asked him about advice to his fellow researchers, and he answered: “There is a famous quote of Dr. Albert Einstein: “If we knew what we were doing, it wouldn’t be called Research”. As postdocs and researchers in general, we are constantly pursuing new hypotheses. It is a very arduous path with its ups and downs but full of rewards and new challenges ahead.” About the future of the antiviral research, he keeps a positive view: “Several antiviral therapies are being developed to combat the current Ebola outbreak, such as antibody cocktails (Zmapp), antiviral drugs, and specific Ebola vaccines. Together with re-purposing screens like the one we published, a combination of therapeutic drugs can be used to obtain better antiviral strategies against the Ebola virus.”

All the bugs in the metro, tube, subway, from NYC to Asia

Buggy Transportation
All the bugs in the metro, tube, subway, from NYC to Asia
By Jesica Levingston Mac leod, PhD

The New York City (NYC) subway is use for more than 5 million passengers per day. Passengers being humans, pets, bacteria, parasites, viruses and other unknown creatures. Consequently infectious diseases, like influenza can be easily transmitted in this transportation method. Other dangerous circumstances are the black carbon and particle matter concentrations, which In Manhattan are considerably higher than in the urban street level. If you have just ridden the subway, I recommend that you check you washed your hands before continue reading…because, literately, this article is about shit!

Last Month a great research team from Cornell published the studies on microorganisms from 466 subway stations where they found 76 known pathogens (aka “bad” bacteria), and, more interestingly, they found a lot of unknown organisms. This means that almost half of all DNA present on the subway’s surfaces matches no known organism. As they could identified some of the microorganisms, they described that these bacteria were originated in some metropolitan citizen food, pet, workplace… you can actually check which kind of bacteria was found in your favorite/closest subway station… just to be sure what to tell to your doctor next time that you have some infection….

During a year and a half, Dr. Mason, the leader of the group, took samples from materials like the metal handrails in order to collect DNA for the big data genetic metropolitan profile project, aka the Pathomap project. From the 15,152 types of life-forms, almost half of the DNA belonged to bacteria—most of them harmless; However, the scientists said the levels of bacteria they detected pose no public-health problem. The most prevalent bacterial species was Pseudomonas stutzeri, with enrichment in lower Manhattan (aka finance species ;)), followed by strains from Enterobacter and Stenotrophomonas. Notably, all of the most consistently abundant viruses (only 0.03%) were bacteriophages, which were detected concomitant with their bacterial hosts.

Other study done in 2013 in Norway, found that the airborne bacterial levels showed rapid temporal variation (up to 270-fold) on some occasions, both consistent and inconsistent with the diurnal profile. Airborne bacterium-containing particles were distributed between different sizes for particles of >1.1 μm, although ∼50% were between 1.1 and 3.3 μm. Anthropogenic activities (mainly human passengers) were the major sources of airborne bacteria and predominantly contributed 1.1- to 3.3-μm bacterium-containing particles. The peaks are at 8 am and 5 pm, following the rush hours.

Other great discovery was that the human allele frequencies in the subway mirrored US Census data. Within the neighborhoods they found African American and Yoruban alleles correlation for a mostly black area in Brooklyn, Hispanic/Amerindian alleles in the Bronx and they observed that Midtown Manhattan showed an increase in British, Tuscan, and European alleles.

In this globalized world, you won’t be surprised that in the London’s Tube a group of journalist and researchers found more than 3 million bacteria. These data suggested that the average train or bus seat could have more than 70 types of bacteria, plus cold and flu viruses. The North-South Victoria line was the only one that passed the hygiene test.

In a study at the Hong Kong subways system, researchers analyzed aerosol samples in order to find the taxonomic diversity of the “under” microbes. Each bacterial community within a line was dependent on architectural characteristics, nearby outdoor micro biomes, and distance to other lines, and were influenced by temperature and relative humidity.

Altogether these results sound really scary, but I hope that the reader won’t react panicking, but just being aware of the bad pathogens around him/her and carry a hand sanitizer/mask/cleaning aerosol/wipes or just wash your hands with soap! Actually, health officials from the FDA, believe washing hands with soap and water is the best method to get rid of germs.

Posts navigation

Cancer DNA: The New Frontier for Preventing and Curing Cancer

Cancer DNA: The New Frontier for Preventing and Curing Cancer
By Jesica Levingston Mac Leod, PhD



DNA Biomarkers are the hot topic in oncology right now, and the more precise, easy and effective they may be to detect cancer, the better. This cutting edge technique has its origins in the discovery that fetuses shed fragments of DNA into the bloodstreams of the mothers, so do normal and cancer cells. The strategy to search for the most accurate “bar code” for each type of cancer is been approach from a bunch of oncologists around the world.

Researchers from the National Cancer institute, MD, published this month in the Lancet, a correlative biomarker study for lymphoma. In the study publish by Roschewski and col., they detected circulating tumor DNA encoding the clonal immunoglobulin gene sequence (VDJ) in the serum of patients with diffuse large-B-cell lymphoma. The VDJ immunoglobulin genes contain unique sequences that are markers of clonality. Malignant cell VDJ gene sequences could be detected in the serum of patients with diffuse large B-cell lymphoma and used to predict clinical disease recurrence after treatment. For this, they used next-generation DNA sequencing to analyze cell-free circulating tumor DNA in patients assigned to one of three different treatment protocols during a period of 20 years. They concluded that “Surveillance circulating tumor DNA identifies patients at risk of recurrence before clinical evidence of disease in most patients and results in a reduced disease burden at relapse. Interim circulating tumor DNA is a promising biomarker to identify patients at high risk of treatment failure.”

Earlier this year, Hyman and col., reported the analysis of a biomarker (the mutant BRAF(V600E)) in 2 systemic histiocytic disorders characterized by accumulation and infiltration of histiocytes in multiple tissues of the body, leading to organ compromise. These researchers from Memorial Sloan Kettering Cancer Center, New York, showed that in plasma and urinary samples cell free DNA provides a reliable method to detect the mutation that is a biomarker for these disorders, and it can monitor response to therapy in these disorders.

In Australia, the group of doctors Tie, Cosgrove and col., identified and validated 3 protein-based biomarkers in independent cohorts of colorectal cancer (n = 145 and n = 197), which could be translated to a reliable, non-invasive blood-based screening test. The biomarker “winners” were selected by Elisa kits, and they are the following proteins: Insulin like growth factor binding protein 2 (IGFBP2), Dickkopf-3 (DKK3), and Pyruvate kinase M2(PKM2). (3) Anyways, this article is bout DNA markers: So, in a follow up study Tie and col. detected circulating tumor DNA in a high proportion of treatment naïve metastatic colorectal cancer patients. Moreover, they described that early changes in circulating tumor DNA during first-line chemotherapy predict the later radiologic response. On other notes, they also reported that the intake of aspirin is not associated with improvements in survival in colon cancer patients, yeah, bad news for the daily aspirin takers.

Studying the blood samples of healthy elders (“wellderlies”, adults age 80 plus), the team lead by doctor Eric Topol, at the SCRIP center, is trying to find the immune response that attacked and effectively destroyed cancer cells. There is a high probability that these healthy elders had had abnormal cell/cells in their bodies at some point of their lives, which they attacked and destroyed, generating immune memory and powerful anti-cancer antibodies. In fact, a member of the team, Doctor Brunie Felding, had discovered that one of the proteins recognized by “wellderly” antibodies was Apolipoprotein E, suggesting that antibodies against this protein may help develop a targeted therapy against highly-expressing ApolipoproteinE cancers.

These new discoveries, plus the recently FDA approval of three new immuno-oncology therapy drugs, called PD-1 inhibitors, are bright examples of the importance of cancer research funding and support from the public to the government officers.

One of the most influential bioinformaticians/molecular biologists, Dr. George Church, genetics professor at Harvard, thinks that “the DNA is the ultimate computer code and we are all computer programmers”. Therefore, the study of the DNA fragments can help to solve multiple problems… it is working for cancer therapy, and it could be useful to treat even the most common disease: aging.

What's Keeping You Up at Night?

What's Keeping You Up at Night?
If you want to sleep, turn off your electronic device.
The light-emitting devices might be keeping you awake!


By Jesica Levingston Mac Leod, PhD



It is well established by now that staring at your phone, iPad or computer screen before going to sleep may delay your “real sleeping” time. The continued exposure to light excites the receptors in your eyes and therefore your brain, sending the signal that you must stay awake longer. This might not be a problem if you enjoy laying around in bed, tossing from side to side, but most people have to get to work early or have other commitments that haunt them the morning after a bad night of sleep. Insomnia is actually a serious disease; the lack of mindful dreaming can have a negative effect in your daytime life, and can result in poor performance at work. A recent study, published in the SLEEP journal, showed that reducing sleep from 8 hours to 4 hours makes memories less accessible in stressful situations.



Last December, a study in Boston added more evidence to the hypothesis that blue light negatively affects the secretion of melatonin, the hormone that helps regulate sleep and wake cycles. Dr. Chang and collaborators published in PNAS that the use of blue light emitting electronic devices before bedtime reduces a person’s alertness and interferes with their circadian rhythm. In this basic study they compared the effects of reading from a light emitting device verses from a paper book. They found that these e-readers delayed sleep for up to an hour compared to the old-fashioned paper books.



A recent study, published in the Journal of Biological Rhythms also tried to answer the question: can access to artificial light modify our sleeping patterns? Their answer was YES, it does! Sounds pretty legit, right?



Dr. De la Iglesia and collaborators studied two native communities in the north of Argentina: the Tobas and the Qom. These two indigenous communities share similar sociocultural and ethnic heritage, but one difference between them is that only the Tobas have access to electricity. Therefore, the Qom community regulates its lifestyle with natural light, like our ancestors before the almighty Mr. Edison’s invention.



The researchers provided the participants from both communities with motion-tracking wristbands to follow their activity during both summer and winter seasons. They found that in the summer season the Tobas had a tendency to get less daily sleep, about 43 min per day, than those living under natural light conditions. Not surprisingly, this was due to a later daily bedtime and sleep onset in the community with electricity, but a similar sleep offset and rise time in both communities. In the winter, the Qoms slept around 56 min per day more than those with access to electricity, and this was also related to earlier bedtimes and sleep onsets than the Tobas. They concluded: “The access to inexpensive sources of artificial light and the ability to create artificially lit environments must have been key factors in reducing sleep in industrialized human societies.”



But reading the conclusion you learn something else: the Toba community had TVs. This caused them to stay awake even later.



How do you get that pleasant sleep? To listen to lullabies… soft melodies ranging from 60 to 80 beats per minute. Take a warm bath, if body temperature drops before bedtime. Another option is to pay extra attention to your breath: focusing on how air moves through your body can relax you and can reduce stress. My favorite solution is to meditate! At least try – a lot of people accidentally fall asleep while trying to meditate anyways ;).



If you are a device-addicted insomniac, at least decrease the brightness of your screen. Tonight, have a nice encounter with Morpheus and remember that the rest of the human race will appreciate not dealing with a cranky sleepless person tomorrow.